Abstract

Progress in understanding kidney disease mechanisms and the development of targeted therapeutics have been limited by the lack of functional in vitro models that can closely recapitulate human physiological responses. Organ Chip (or organ-on-a-chip) microfluidic devices provide unique opportunities to overcome some of these challenges given their ability to model the structure and function of tissues and organs in vitro. Previously established organ chip models typically consist of heterogenous cell populations sourced from multiple donors, limiting their applications in patient-specific disease modeling and personalized medicine. In this study, we engineered a personalized glomerulus chip system reconstituted from human induced pluripotent stem (iPS) cell-derived vascular endothelial cells (ECs) and podocytes from a single patient. Our stem cell-derived kidney glomerulus chip successfully mimics the structure and some essential functions of the glomerular filtration barrier. We further modeled glomerular injury in our tissue chips by administering a clinically relevant dose of the chemotherapy drug Adriamycin. The drug disrupts the structural integrity of the endothelium and the podocyte tissue layers, leading to significant albuminuria as observed in patients with glomerulopathies. We anticipate that the personalized glomerulus chip model established in this report could help advance future studies of kidney disease mechanisms and the discovery of personalized therapies. Given the remarkable ability of human iPS cells to differentiate into almost any cell type, this work also provides a blueprint for the establishment of more personalized organ chip and ‘body-on-a-chip’ models in the future.

Highlights

  • Established kidney glomerulus chip devices employed podocytes and endothelial cells derived from different sources and individuals, and these organon-a-chip devices contained tissue layers with unmatched genetic backgrounds

  • While the use of animal cells is limited in physiological translation into humans, even the use of primary, immortalized, or amniotic fluid-derived cells are limited in their multipotency and/or availability

  • DU-11 human induced pluripotent stem (iPS) cells produced from a single donor were used to derive human intermediate mesoderm (IM) and vascular endothelial cells (Figure 1a)

Read more

Summary

Introduction

More than 15% of U.S adults have chronic kidney disease (CKD), and many people are unaware that they have the disease due to the lack of early diagnostic tools or methods [1]. CKD progresses into end-stage kidney disease, which is estimated to increase in the US by. 11–18% by 2030, partly due to an increased prevalence of diabetes and hypertension—the leading causes of CKD [2,3,4]. For patients suffering from CKD, the quality of life (including physical and mental health) is greatly decreased [5]. Dialysis and transplantation are still the only treatment options for kidney dysfunction

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call